New clinical trial will explore palm-derived STGaia and its impact on healthy aging

In a July 21, 2025, press release, palm-derived phytonutrients supplier PhytoGaia announced the approval for a new, six-month clinical trial on the effects of its proprietary STGaia on health aging. The patent-pending complex of plant squalene with tocotrienols/tocopherol is extracted from palm-fruits and is intended for visible and systemic healthy aging factors. STGaia is currently in commercial products, used for skin and hair health, cognition, and emotional resilience.

The randomized, double-blind, placebo-controlled human clinical trial is titled, “Plant Squalene and Tocotrienols Complex in Aging: Exploring Their Role in Telomere Preservation and Cellular Longevity,” and will examine the two biomarkers of aging as its primary focus. Additional evaluations will involve NAD+/NADH ratio, ATP levels, antioxidant enzyme activity, inflammation markers, and expression of certain genes.

The study will be conducted in partnership with Monash University Malaysia, and recruitment for participants, ages 50–75, is expected soon.

“With the recent publication of a clinical study on full spectrum palm tocotrienols (TocoGaia) in healthy aging, this new trial with STGaia marks an exciting next chapter in our ongoing exploration of palm phytonutrients and their role in cellular health and longevity,” stated Bryan See, vice president of PhytoGaia, in the press release. “It underscores our continued commitment to human clinical research in aging and longevity. We’re proud to collaborate once again with Monash University – one of the world’s top academic institutions – as we investigate STGaia’s potential in preserving telomere length and supporting genomic integrity at the cellular level.”

“This study represents an exciting opportunity to investigate how our local naturally derived bioactives such as tocotrienols and squalene may modulate cellular aging pathways,” stated Ammu Radhakrishnan, principal investigator at Monash University Malaysia. “We look forward to this collaboration to explore the potential of STGaia to support genomic stability, telomere health, and overall longevity through a rigorous, science-based approach.”

“Building on current scientific findings, we believe that the synergy between tocotrienols and plant squalene represents a novel approach to healthy aging,” stated Ariati Aris, scientific affairs specialist at PhytoGaia. “This trial will deepen our understanding of the mechanisms behind STGaia’s multi-targeted benefits and further strengthen its clinical validation in longevity and healthy lifespan solutions.”